We are a group of motivated immunologists committed to delivering the power of cytokines to patients.

Founded in 2017 by leading experts in the field of immunotherapy, Anaveon is a biopharmaceutical company that specializes in the development of treatments for diseases with immune system dysfunction.

Our goal is to harness the power of engineered cytokines and develop novel treatments for diseases with high unmet need.

Years of Experience

Million CHF Funding

Days to regulatory submission

LATEST NEWS

Our dedicated team of experts has decades of experience in immunology, oncology and drug design. We use our deep knowledge to deliver novel drugs that address unmet medical needs.

About us

We are committed to developing treatments that benefit patients.

Science

We are developing an IL-2 immunotherapy for cancer.

Team

We are driven by the urgency of patients.

Investors
&
Partners

We are backed by more than 36 million CHF (€34 million) of funding.